Milacemide

Milacemide
Names
	IUPAC name 2-(Pentylamino)acetamide
Identifiers
CAS Number	76990-56-2 ;
3D model (JSmol)	Interactive image; Interactive image;
ChEMBL	ChEMBL75838 ;
ChemSpider	48376 ;
MeSH	milacemide
PubChem CID	53569;
UNII	0HXT24RECU ;
CompTox Dashboard (EPA)	DTXSID10227786 ;
	InChI InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10) Key: GJNNXIYZWIZFRH-UHFFFAOYSA-N ;
	SMILES CCCCCNCc(:[nH2]):[o]; CCCCCNCC(N)=O;
Properties
Chemical formula	C7H16N2O
Molar mass	144.218 g·mol−1
log P	0.754
Related compounds
Related compounds	Tricine
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Milacemide (INN)^[2] is an MAO-B inhibitor and glycine prodrug.^[3] It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.^[4] Early clinical trials did not show positive results however,^[3] and the drug is now abandoned.

References

^ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.
^ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.
^ ^a ^b Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type". Journal of the American Geriatrics Society. 40 (5): 503–6. PMID 1634705.
^ Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X.{{cite book}}: CS1 maint: multiple names: authors list (link)

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.

[2] "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.

[Dysken-3] Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type". Journal of the American Geriatrics Society. 40 (5): 503–6. PMID 1634705.

[4] Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X.{{cite book}}: CS1 maint: multiple names: authors list (link)

[1]

[2]

[3]

[4]